Being an M&A focused newsletter, this is required reading for all of you. When you're holding biotech and banking names that are active acquisition targets, covered calls can be a great way to hedge volatility and generate income while you wait for catalysts. But there's a real risk when a buyout hits and your calls are in the money. This breaks it all down clearly. Worth the read.